Trial Outcomes & Findings for Ketoconazole Foam 2% for the Treatment of Versicolor (NCT NCT00830388)

NCT ID: NCT00830388

Last Updated: 2012-08-22

Results Overview

Eleven participants were tested for the microscopic presence of yeast. At four weeks, all participants were re-tested and deemed positive if yeast continued to be present microscopically.

Recruitment status

COMPLETED

Study phase

PHASE4

Target enrollment

11 participants

Primary outcome timeframe

4 weeks

Results posted on

2012-08-22

Participant Flow

Participant milestones

Participant milestones
Measure
Ketoconazole 2% Foam
Open-label study using Ketoconazole 2% foam applied twice daily to all affected areas for 2 weeks.
Overall Study
STARTED
11
Overall Study
COMPLETED
11
Overall Study
NOT COMPLETED
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Ketoconazole Foam 2% for the Treatment of Versicolor

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Ketoconazole 2% Foam
n=11 Participants
Open-label study using Ketoconazole 2% foam applied twice daily to all affected areas for 2 weeks.
Age, Categorical
<=18 years
0 Participants
n=5 Participants
Age, Categorical
Between 18 and 65 years
11 Participants
n=5 Participants
Age, Categorical
>=65 years
0 Participants
n=5 Participants
Sex: Female, Male
Female
8 Participants
n=5 Participants
Sex: Female, Male
Male
3 Participants
n=5 Participants
Region of Enrollment
United States
11 participants
n=5 Participants

PRIMARY outcome

Timeframe: 4 weeks

Eleven participants were tested for the microscopic presence of yeast. At four weeks, all participants were re-tested and deemed positive if yeast continued to be present microscopically.

Outcome measures

Outcome measures
Measure
Ketoconazole 2% Foam
n=11 Participants
Open-label study using Ketoconazole 2% foam applied twice daily to all affected areas for 2 weeks.
The Effect of Ketoconazole 2% Foam for the Treatment of Tinea Versicolor
Negative skin sample
7 participants
The Effect of Ketoconazole 2% Foam for the Treatment of Tinea Versicolor
Positive skin sample
4 participants

SECONDARY outcome

Timeframe: 4 weeks

Adverse events were used to assess safety.

Outcome measures

Outcome measures
Measure
Ketoconazole 2% Foam
n=11 Participants
Open-label study using Ketoconazole 2% foam applied twice daily to all affected areas for 2 weeks.
To Assess the Safety of Ketoconazole 2% Foam for the Treatment of Tinea Versicolor Based on the Occurrence of Adverse Events.
0 events

Adverse Events

Ketoconazole 2% Foam

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Wendy Cantrell

University of Alabama at Birmingham

Phone: 205-502-9960

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place